MPP Group mppgroup.net


Public lists: Pharma Startups (4732)

MPP Group is a global pharmaceutical company that specializes in small molecule APIs that serve a variety of acute and chronic clinical needs.

MPP Group is a global pharmaceutical company that specializes in small molecule APIs that serve a variety of acute and chronic clinical needs.

Company (Alive / Active)

Phone: 714-879-4949

Fax:

3200 Enterprise Street
Brea, 92821
California, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
MPP Group $0M Nov 30, 2018
See all 14 competitors

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related MPP Group Jobs

jobs by Indeed job
						search

Investors

Investor Investor Type Location Participating Rounds
See all 1 investors
There is no Board of Directors data available for this company. Please select another tab.

Competitors

Company Status Description Investors

Alexza Pharmaceuticals

Mountain View, California, United States
AcquiredAlexza is developing drugs for acute and intermittent medical conditions. Their Staccato system aerosolizes without thermal degradation, enabling convenient delivery and rapid therapeutic onset of many small molecule drugs. The company has product candidates in clinical trials for migraine headaches, acute panic attacks, acute agitation in schizophrenia and acute pain.Login to see details

CVRx

Minneapolis, Minnesota, United States
Alive / ActiveCVRx is a privately held company founded in 2001 and headquartered in Minneapolis, Minnesota. The company has developed the second-generation BAROSTIM NEO, a minimally-invasive implantable system and the only device CE Marked for the separate indications of heart failure and resistant hypertension. BAROSTIM NEO is commercially available in over 20 countries and under clinical evaluation for the treatment of heart failure and hypertension in the United States. The company's BAROSTIM NEO LEGACY ho...Show allLogin to see details
See all 14 competitors

Patents

Title Application Date Patent Date Status
(Patent / Application)